Technologies Enabling Next Generation Vaccine Development

Technologies Enabling Next Generation Vaccine Development

Upcoming Vaccine Technologies for Infectious Diseases

RELEASE DATE
02-May-2019
REGION
Global
Research Code: D8AB-01-00-00-00
SKU: HC03170-GL-TR_23102
AvailableYesPDF Download
$4,950.00
In stock
SKU
HC03170-GL-TR_23102
$4,950.00
DownloadLink
ENQUIRE NOW

Description

Vaccine Delivery platforms: This section covers various nanoparticle-based vaccine delivery platforms such as nanoparticles of biological (self-assembling proteins) and non-biological origin ( inorganic and polymeric). The biological nanoparticles subsection overlaps with virus-like particles that has been separately addressed.

Virus-Like Particles: Virus-Like Particles are biological nanoparticles having size of around 20-100 nm. Due to the repetitive nature, viral capsid proteins have tendency to self-assemble. Lack of genetic material makes them non-replicative and hence safe vaccines. Therefore, VLPs are gaining a lot of attractions from vaccine development point of view.

Bacterial and fungal vaccines: This part discusses upcoming vaccines which can protect against multiple bacterial and fungal infections, toxoid vaccines, neutralizing antibodies and new technologies like carbohydrate-conjugate vaccines, surface antigen vaccines etc.

Synthetic vaccines: The segment of synthetic vaccines talks about the short, long and synthetic peptide vaccines against viral and bacterial diseases, innovative T cell stimulating immunogens and fusion proteins.

Viral vector-based vaccines: It covers genetically modified viral vectors which are engineered to make replication incompetent by deletion of essential genes or highly attenuated viral vectors that lack pathogenic genes.

Adjuvant technology: Unique lipid-based adjuvants, oil-in-water adjuvants, plant-derived adjuvants, synthetic and immune-cell-receptor based adjuvants as well as virosomes (derived from viral proteins) are reviewed here.

Vaccine synthesis, formulation and delivery platforms: This section partially overlaps with virus-based vaccine delivery platforms like virosomes, synthetic and modified-viral platforms, cell-free protein synthesis and gene delivery methods and proprietary cell lines used for vaccine production.

Table of Contents

1.1 Research Scope: Vaccine Technologies Under Development Phase

1.2 Analysis Framework: Frost & Sullivan Core Value

1.3 Research Methodology: Five Steps Toward Success

1.4 Key Findings of Global Vaccine Technology Development

2.1 Research Scope: Current Status and Challenges of Vaccine Development

2.2 Technologies Transforming Next-generation Vaccines

3.1 Nanoparticles Enable Efficient and Safe Vaccine Delivery

3.2 Self-assembling Nanoparticles of Biological Origin

3.3 Polymeric and Inorganic Nanoparticles for Vaccine Delivery

4.1 Virus-like Particles Mimic The Real Viral Infection

4.2 Landscape of VLP-based Vaccines, Global, 2019

4.3 Influenza Shares A Major Portion of VLP-based Vaccines

4.4 Multiple Adaptations of VLP Technology for Vaccine Development

4.5 Plant Leaves Producing A Wide Variety of VLPs

5.1 Emerging Technologies for Bacterial and Fungal Vaccines

5.2 Emerging Bacterial and Fungal Vaccines, Global, 2019

5.3 New Strategies for Bacterial and Fungal Vaccines

5.4 Novel Vaccines & Therapeutics for Emerging Infectious Diseases

5.5 Multi-protein Complex-based Bacterial Vaccines

5.6 Carbohydrates-based or Conjugate Vaccines

6.1 Development Status of Synthetic Vaccines, Global, 2019

6.2 Peptides-based Vaccine Technologies

6.3 Genetically Modified Vaccines for HIV and Streptococci

7.1 Overview of Viral Vector-based Vaccines

7.2 Summary of Developing Viral Vector Vaccine Technology, Global, 2019

7.3 Diverse Replication-incompetent Viral Vaccines

7.4 Replication-incompetent Viruses with Nasal Spray Formulation

7.5 Live Attenuated Influenza Vaccines with Nasal Formulation

7.6 Viral Vector Vaccines for Serious Human Diseases

Flu vaccine based on regions of limited variability

8.1 Novel Lipid Formulations as Adjuvant

8.2 Oil-in-water Nanoemulsion and Saponin-based Adjuvants

8.3 Toll-like Receptor-based Adjuvants

9.1 Synopsis of Vaccine Synthesis, Formulation Delivery Platforms

9.2 Cell-free and Cell-based Vaccine Synthesis Platforms

9.3 Diverse Vaccine Formulation Technologies

9.4 Needle-less Solid Dose Vaccine Delivery Formulation and Device

9.5 Gold Nanoparticles and Applications in Vaccine Delivery

9.6 Nanopatch, Recombinant Protein and Lipid-based Carriers

10.1 Growth Opportunity 1: Influenza Vaccines

10.2 Growth Opportunity 2: Vaccines for Vector Borne Viral Diseases

10.3 Growth Opportunity 3: Vaccine Delivery Technologies

10.4 Strategic Imperatives for Success and Growth

11.1 Industry Interactions

Legal Disclaimer

Related Research
Vaccine Delivery platforms: This section covers various nanoparticle-based vaccine delivery platforms such as nanoparticles of biological (self-assembling proteins) and non-biological origin ( inorganic and polymeric). The biological nanoparticles subsection overlaps with virus-like particles that has been separately addressed. Virus-Like Particles: Virus-Like Particles are biological nanoparticles having size of around 20-100 nm. Due to the repetitive nature, viral capsid proteins have tendency to self-assemble. Lack of genetic material makes them non-replicative and hence safe vaccines. Therefore, VLPs are gaining a lot of attractions from vaccine development point of view. Bacterial and fungal vaccines: This part discusses upcoming vaccines which can protect against multiple bacterial and fungal infections, toxoid vaccines, neutralizing antibodies and new technologies like carbohydrate-conjugate vaccines, surface antigen vaccines etc. Synthetic vaccines: The segment of synthetic vaccines talks about the short, long and synthetic peptide vaccines against viral and bacterial diseases, innovative T cell stimulating immunogens and fusion proteins. Viral vector-based vaccines: It covers genetically modified viral vectors which are engineered to make replication incompetent by deletion of essential genes or highly attenuated viral vectors that lack pathogenic genes. Adjuvant technology: Unique lipid-based adjuvants, oil-in-water adjuvants, plant-derived adjuvants, synthetic and immune-cell-receptor based adjuvants as well as virosomes (derived from viral proteins) are reviewed here. Vaccine synthesis, formulation and delivery platforms: This section partially overlaps with virus-based vaccine delivery platforms like virosomes, synthetic and modified-viral platforms, cell-free protein synthesis and gene delivery methods and proprietary cell lines used for vaccine production.
More Information
No Index No
Podcast No
Author Harshal Patil
Industries Healthcare
WIP Number D8AB-01-00-00-00
Is Prebook No